Blog

Besides strong expertise with CAD,  EDDA’s  image analytics workflow solutions go beyond detection into diagnosis and treatment management decision support

Mountainview, CA June 14, 2011 Frost & Sullivan Release

Based on its recent analysis of the medical imaging analytics market, Frost & Sullivan recognizes EDDA Technology (EDDA) with the 2011 North American Frost & Sullivan Award for Technology Innovation. Technology innovation is a core cultural value of EDDA, which it has successfully leveraged to pursue best-in-class expertise with multi-modality imaging analytics, while expanding its scope and capabilities to provide complete workflow solutions of computer assisted decision support for radiology and surgery.

“Studies have shown that the death rates of lung and liver disease, some of the highest in the U.S., can be improved effectively through early detection and intervention, making them among the best candidates for meaningful technology innovation,” said Frost & Sullivan Principal Analyst Nadim Daher. “EDDA has continually delivered to its customers and OEM partners, breakthrough technology and innovative products, especially in the areas of computer-aided detection (CAD) and decision support for diagnosis and treatment.”

Already a top provider of CAD solutions for lung and liver imaging using multiple modalities including multi-detector computed tomography (MDCT), digital radiography (DR), EDDA is further moving into magnetic resonance imaging (MRI) and other clinical applications. In the area of digital X-ray for low dose high performance solutions, EDDA is pioneering the imaging industry’s research and development (R&D) efforts towards using CAD for DR Tomosynthesis. EDDA is also leveraging its core competency in real-time quantitative imaging analysis to embark on the R&D of multi-modality intra-operative imaging applications for interventional procedures and surgeries in modern operation suites.

In addition, EDDA has adopted both an organ focus as well as a disease focus to develop a complete portfolio of image analytics solutions going well beyond the traditional CAD functions. EDDA has designed these solutions with an enterprise perspective in mind, as they cater to the needs of not just individual clinical departments, but of the entire, diverse and multi-disciplinary teams that act across the continuum of care.

In the case of liver disease, for example, EDDA’s  IQQA®-Liver platform coordinates the workflow of multiple stakeholders along the cycle of liver care, including radiologists, interventional radiologists, transplantation and other liver surgeons and oncologists. It is the industry’s most comprehensive workflow solution for liver care and is being well received by the marketplace. In fact, the IQQA Enterprise Engine allows integrating EDDA’s as well as other third party image analytics applications into virtually any OEM PACS system.

“In essence, EDDA’s value proposition is to leverage sophisticated image analytics applications to provide enhanced clinical efficiency and effectiveness in healthcare imaging,” said Daher. ”Through its clinical depth and enterprise-wide breadth, EDDA’s solution set aligns perfectly well with the paradigm shifts taking place in the U.S. healthcare system, as it trends towards more IT workflow-based collaboration between radiologists and their enterprise customers on one hand, and towards a tighter connection between detection, diagnosis, pre-treatment planning as well as post-treatment evaluation follow-up on the other hand.”

EDDA fared relatively well through the industry wide slowdown in 2009, which has shown that solutions having such high clinical significance have been least affected by financial austerity measures at the top level of department and hospital budgets. During this period, EDDA continued to grow its direct customer base of hospital facilities, while maintaining a solid OEM business partnering with leading imaging equipment industry vendors including Philips and Shimadzu. In fact, some of these industry partnerships have been taken to the next level of collaborative research and development partnerships. Overall, EDDA is extremely well positioned at the forefront of the next phase facing the industry.

In recognition of these achievements, Frost & Sullivan is proud to present EDDA with the 2011 North American Technology Innovation Award in medical imaging analytics. Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing a technology, which significantly impacts both the functionality and the customer value of new products and applications. The award lauds the relevance of the innovation to the industry.

Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices in the industry.

About EDDA Technology

EDDA Technology, Inc. is an innovative clinical computer solution provider in healthcare imaging and analysis. EDDA offers a series of next generation computer assistance solutions to the entire patient care management cycle, including enabling early detection and diagnosis of diseases, as well as enhancing efficiency and precision in treatment planning, management and follow-up. EDDA’s goal is to deliver, with broad accessibility, advanced information analysis technologies that improve clinical workflow and accuracy. A privately held Delaware corporation, EDDA is headquartered in Princeton, New Jersey, and has a subsidiary in Shanghai, China. IQQA® is a registered trademark of EDDA Technology. http://www.eddatech.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.awards.frost.com.

Contact:
Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003
E: mireya.espinoza@frost.com

PRINCETON, NJ, January 7, 2011

EDDA Technology, a leading provider of advanced computer assisted radiology and surgery solutions, announces today the successful commercial installation of its IQQA®-Liver Enterprise product at Mayo Clinic, Scottsdale, AZ.

As one of the top performing living donor liver transplantation programs in the US, Mayo Clinic will
use EDDA Technology’s IQQA®-Liver Enterprise in conjunction with its existing technologies by a
multidisciplinary team of surgeons and radiologists.

With an innovative toolset for real-time interactive assessment and volumetric quantification of
liver, liver lobes, vessels, and other intra-hepatic anatomies, IQQA®-Liver helps physicians
enhance efficiency and precision in pre-operative treatment planning and post-surgical follow-up
assessment. EDDA’s proprietary technology has been used to evaluate more than 1,000 clinical
cases at liver surgery/transplantation centers worldwide since the first commercial installation in
2009. IQQA®-Liver has clearance by the FDA and China SFDA, and carries the CE mark.

“To understand each individual’s liver anatomy in a quantitative way is essential to ensure the
most suitable surgical approach,” said David Mulligan, M.D., Chair of Division of Transplant
Surgery at Mayo Clinic in Arizona. “EDDA’s IQQA®-Liver provides us a comprehensive,
quantitative, real-time tool for better treatment planning with confidence. The ability to make
accurate calculations and change potential surgical approaches within minutes allows safe
planning at optimal patient convenience.”

“The successful installation of IQQA®-Liver Enterprise at Mayo Clinic indicates that the value of
our technology is once again recognized in assisting physicians to fully utilize the benefits of
quantitative imaging modalities.” said Dr. Jian-Zhong Qian, President and CEO of EDDA
Technology. “EDDA is fully committed to providing total solutions for better liver disease/patient
management through its innovative technologies in diagnosis, pre-operative treatment planning,
intra-operative guidance, post-operative assessment and follow-up.”

Typical IQQA® -Liver results achieved within minutes on details of intra-hepatic anatomies

About EDDA Technology
EDDA Technology, Inc. is an innovative clinical computer solution provider in healthcare imaging
and analysis. EDDA offers a series of next generation computer assistance solutions to the entire
patient care management cycle, including enabling early detection and diagnosis of diseases, as

Press Release
well as enhancing efficiency and precision in treatment planning, management and follow-up.
EDDA’s goal is to deliver, with broad accessibility, advanced information analysis technologies
that improve clinical workflow and accuracy. A privately held Delaware corporation, EDDA is
headquartered in Princeton, New Jersey, and has a subsidiary in Shanghai, China. IQQA® is a
registered trademark of EDDA Technology. HUwww.eddatech.comUH

Editor’s Note:
EDDA Technology will be exhibiting the IQQA®-Liver product in booth #110 at the
11th Annual Winter Symposium of the American Society of Transplant Surgeons
in Hollywood, FL, January 13-16, 2011.

PRINCETON, NJ, November 23rd, 2010

EDDA Technology announced today that it will introduce its innovative IQQA®-Liver Suite, which provides dedicated total solutions for liver cancer diagnosis and operative treatment management, at the 96th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA). For better healthcare and patient management, the IQQA®-Liver Suite aims to enhance efficiency and precision in liver disease diagnosis, pre-operative treatment planning, intra-operative guidance, post-surgical assessment and follow-up.

The IQQA®-Liver Suite addresses the challenges of modern multidisciplinary advanced quantitative imaging evaluation and management, which often require the sharing of processing/analysis result in a real-time interactive/conferencing fashion, simultaneously and collaboratively from multiple departments in different locations. The IQQA®-Liver Suite utilizes EDDA’s proprietary IT technology to streamline system platform architectural and workflow design. It not only offers immediate integration with hospitals’ existing PACS systems, but also allows access to the 4-D IQQA®-Liver application for volumetric quantitative assessment and virtual operative simulations from anywhere anytime via the IQQA® On Demand Internet platform. Furthermore, a virtual session may be created to allow simultaneous accesses to and manipulations of the same dataset, where conferencing/collaboration from multiple department/locations becomes easy to manage.

At the core of the suite, IQQA®-Liver, an advanced 4-D image quantitative evaluation system, is currently used by radiologists and surgeons worldwide in liver surgery, transplantation and interventional centers. The number of clinical image cases evaluated for pre- and post- operative assessment using IQQA®-Liver in hospitals has exceeded 1000 examinations, since the first commercial system installation in Q2 2009. This innovative toolset assists physicians to perform fast real-time interactive assessment and volumetric quantification of liver, liver lobes, hepatics lesions and vessels from liver imaging data, as well as virtual simulation of resection, lobular/vascular manipulation and quantification to achieve desired treatment planning. In many instances, the use of quantitative IQQA®-Liver helps to facilitate the planning of precision treatment procedures on very challenging cases.

Using an individualized 3D E-Liver map generated by IQQA®-Liver, IQQA®-Guide (works-in-progress) of this suite further provides a real-time quantitative 3D navigation guide to assist physicians during interventional and surgical procedures. The system also provides quantitative risk analysis as well as territory/vascular analysis with quantified volumetry on targeted regions of interest during the guidance process. The intra-operative IQQA®-Guide organically links the pre-surgical planning and post surgical assessment together to help physicians optimize the liver tumor management process.

EDDA Technology will be exhibiting other IQQA® Family of Products in Booth #8950 at the RSNA 2010, including IQQA®-Chest Enterprise CAD (Computer Aided Detection) for assisting physician’s detection of small lung nodules from digital chest X-ray, and IQQA® –TomoS CAD (works-in-progress) for Digital X-ray Tomosynthesis. The first prospective study on chest X-ray CAD published in journal (Academic Radiology Vol. 15:5) demonstrated a significant sensitivity increase of physician’s nodule detection from 63.8% without IQQA®-Chest to 92.7% with IQQA®-Chest assistance (while specificity kept high at 96.2% from the previous 98.1%).

Typical IQQA®-Liver results achieved within minutes on details of intra-hepatic anatomies

About EDDA Technology
EDDA Technology, Inc. is an innovative clinical computer solution provider in healthcare imaging and analysis. EDDA offers a series of next generation computer assistance solutions to the entire patient care management cycle, including enabling early detection and diagnosis of diseases, as well as enhancing efficiency and precision in treatment planning, management and follow-up. EDDA’s goal is to deliver, with broad accessibility, advanced information analysis technologies that improve clinical workflow and accuracy. A privately held Delaware corporation, EDDA is headquartered in Princeton, New Jersey, and has a subsidiary in Shanghai, China. IQQA® is a registered trademark of EDDA Technology. www.eddatech.com

AuntMinnie.com | August 19, 2010 | Advanced Visualization Community

By Erik L. Ridley

Quantitative image analysis may be able to significantly increase the number of living liver donors, according to research from the University of Colorado School of Medicine in Aurora.

Re-evaluation of previously rejected living liver donor patients with a quantitative image analysis system found that nearly half had suitable anatomy for transplantation. If these results are validated, the technology could significantly affect the number of living liver donors and the total number of livers available for transplantation, according to the researchers.

Paul Russ, MD, and colleagues presented their study this week in a poster presentation at the Transplantation Society (TTS) 2010 International Congress in Vancouver.

The group retrospectively studied 30 potential adult living liver donors who were rejected as donor candidates between April 2007 and October 2009. These patients initially underwent hepatic anatomy analysis using a conventional CT protocol that included CT angiography, venography, and cholangiography.

Armed only with the knowledge that the patients had been rejected as liver donors, the study team submitted the same CT data for retrospective analysis using IQQA-Liver quantitative image analysis software (EDDA Technology, Princeton, NJ). The system provides real-time interactive analysis of the liver and intrahepatic anatomies and their spatial relationships based on advanced segmentation, according to the researchers.

The software’s segmentation results can be confirmed or adjusted by the user based on the original CT images. Volumes are then calculated accordingly and surgical plans can be interactively modeled, according to Russ and colleagues.

The system allowed for both left and right liver volumes to be interactively determined in real-time. In each case, hepatic artery, hepatic vein, portal vein, and bile duct anatomy and volumes were evaluated with user-confirmed 3D visual and volumetry information, according to the researchers.

Using the same criteria applied in their original assessment, patients were designated as either suitable or unsuitable to serve as a living liver donor based on a confidence scale of 1 (least certain) to 5 (most certain). The researchers then compared the new rating with the results with the original findings.

Of the 30 patients originally rejected, 29 (97%) were previously declined due to unsuitable hepatic anatomy. Fourteen (48%) of these patients were judged to have suitable anatomy transplantation following quantitative imaging analysis.

Two cases had a confidence level of 5, while eight had a confidence level of 4. Four cases had a confidence level of 3.

As for the 15 cases that were still determined to be unsuitable following quantitative image analysis, eight (53%) had hepatic vein abnormalities and seven (47%) had portal vein abnormalities. Four cases (27%) had bile duct abnormalities, while three cases (20%) had hepatic artery abnormalities. Three cases (20%) had small left lobe liver volumes, with a mean value of 24% of the total liver volume.

Due to unsuitable anatomy, five cases (33%) were rejected solely due to hepatic vein abnormalities, three cases (20%) solely due to portal vein abnormalities, one case (7%) solely due to bile duct abnormalities, one case (7%) solely due to small left lobe volume, and five cases (33%) due to a combination of abnormalities, according to the researchers.

“Preliminary results suggest that [living liver donor] assessment could benefit from quantitative analysis and interactive evaluation of liver anatomy in a virtual way using the quantitative imaging analysis system,” the researchers concluded in their study abstract.

PRINCETON, NJ, August 12, 2010

EDDA Technology announced today that the number of clinical cases evaluated for pre- and post- operative assessment using IQQA®-Liver in hospitals has exceeded 1000 examinations, since the first commercial system installation in Q2 2009. EDDA’s IQQA®-Liver, now marketed worldwide, is a comprehensive workflow solution supporting modern multidisciplinary liver imaging evaluation and management.

Primary liver cancer represents one of the most common malignancies in the world and accounts for almost 1.25 million deaths annually. In the US, liver disease is among the ten major causes of death. The management of hepatic tumors presents a challenging problem. Advanced preoperative imaging assessment is paramount in determining appropriate treatment, and requires the participation of a multidisciplinary team of surgeons, oncologists, hepatologists, and interventional radiologists specializing in liver malignancy.

IQQA®-Liver is designed to cope with such a challenge. It provides an innovative toolset for real-time interactive assessment and volumetric quantification of liver, liver lobes, hepatics lesions and vessels. With the intuitive and easy-to-use tools, physicians may in real-time perform virtual simulation of resection, lobular/segmental/vascular manipulation and quantification to achieve desired planning result typically within minutes.

EDDA’s proprietary IT technology allows enterprise-wide deployment of IQQA®-Liver via web so as to quick share data and results anywhere anytime among the multidisciplinary liver team.
IQQA®-Liver has clearance by the FDA, China SFDA, Taiwan DOH, and carries the CE mark. It is currently in use at numerous prestigious liver transplantation/surgery/interventional centers worldwide, including University of Colorado Hospitals Denver, Shanghai Zhongshan Hospital, Shanghai Ruijin Hospital, Tianjin First Center Hospital, Beijing You’an Hospital, Nanjing Gulou Hospital and etc.

In one study, University of Colorado Hospital Denver used IQQA®-Liver to retrospectively evaluate the entire living liver donor (LLD) candidate studies rejected in a 2 year period, and found that about 48% that were previously rejected due to anatomic abnormalities by conventional CT visualization could have favorable anatomy for LLD. According to Dr. Igal Kam, Chief of Transplantation, and Dr. Paul Russ, Professor of Radiology, “IQQA®-Liver allows for better understanding of surgical anatomy and surgical planning in the preoperative evaluation. This will have positive outcome on available livers and LLD selection.” Results will be presented at the XXIII International Congress of the Transplantation Society in Vancouver. EDDA will exhibit IQQA®-Liver at this congress (booth #38).

Press Release

Results using IQQA®-Liver achieved within minutes on details of intra-hepatic anatomies

Results using IQQA®-Liver achieved within minutes on details of intra-hepatic anatomies

About EDDA Technology
EDDA Technology, Inc. is an innovative clinical computer solution provider in healthcare imaging and analysis. EDDA offers a series of next generation computer assistance solutions to the entire patient care management cycle, including enabling early detection and diagnosis of diseases, as well as enhancing efficiency and precision in treatment planning, management and follow-up.
EDDA’s goal is to deliver, with broad accessibility, advanced information analysis technologies that improve clinical workflow and accuracy. A privately held Delaware corporation, EDDA is headquartered in Princeton, New Jersey, and has a subsidiary in Shanghai, China. IQQA® is a registered trademark of EDDA Technology. www.eddatech.com

AuntMinnie.com | June 18, 2010

By Lin Muschlitz

When used as a second reader by an experienced chest radiologist, chest radiography computer-aided detection (CAD) technology can yield a high level of sensitivity, specificity, and accuracy in detecting lung nodules, according to a recent study published in the Journal of Digital Imaging.

The retrospective study, led by William Moore, MD, of Stony Brook University Hospital in Stony Brook, NY, found a particular benefit in improving specificity for detecting nodules 5 to 15 mm in size (J Digit Imaging, March 31, 2010).

“If you use this device as it’s intended, as a second look, something to bring your attention to an area, your specificity can be in the mid-80s [and] accuracy around high 70 [or] low 80 percentile,” Moore told AuntMinnie.com. “That’s pretty spectacular when you’re talking about pulmonary nodules between 5-mm and 15-mm size.”

The research team sought to determine the performance of a chest radiography CAD system in patients referred to chest CT angiography (CTA); CTA was used as a reference standard.

The study included 240 patients from November 2007 to November 2008 who had CT-confirmed nodules and a posteroanterior radiograph within a 24-hour time frame.

All of the chest radiographs were manually sent to a U.S. Food and Drug Administration (FDA)-cleared chest radiography CAD system, the IQQA-Chest CAD (EDDA Technology, Princeton, NJ), as a DICOM image. CTA images were generated using a LightSpeed 4 scanner (GE Healthcare, Chalfont St. Giles, U.K.).

Only nodules between 0.5 and 1.5 cm were analyzed in the study. The IQQA-Chest CAD system is designed to ignore any nodule outside of these parameters.All imaging studies were performed from the lung apex to the lung bases.

CAD findings were scored from 1 to 5:

1. Definitely not a nodule
2. Probably not a nodule
3. Unsure
4. Probably a nodule
5. Definitely a nodule

The chest radiographs were exposed at 100 kV with a 10:1 grid and were obtained using a FCR 9501 computed radiography system (Fujifilm Medical Systems USA, Stamford, CT). The CTA and the chest radiographs were evaluated at different times by the same experienced thoracic radiologist to avoid bias.

Of the total 69 CTA-confirmed nodules in 49 patients, two were found to be malignant, one at 1.2 cm and the other at 1.4 cm. Four other nodules were densely calcified (likely benign granulomas) and included as true nodules; CTA and chest radiography identified all four. All other nodules are currently in a follow-up protocol.

Of the 165 CAD findings or regions of interest (ROIs) on chest radiography, 49 were actual nodules seen on CTA. No definitive correlation with size of the nodule and CAD detection of the nodule was noted. There were 121 cases where there was no CAD ROI, and the CTA showed no nodules between 5 and 15 mm.

False-positive ROIs totaled 116, achieving an overall sensitivity of 71% and a specificity of 50%. The sensitivity decreased to 69% when excluding the four granulomas. Eighty-seven of the 165 findings received a score of 1 or 2 by the radiologist and were easily dismissed. The CAD software produced 71.5% false-positive ROIs.

CTA demonstrated no nodule or other abnormality in this region. Specificity was 78% and accuracy was 74%. Five ROIs ranked as either 1 or 2 by the radiologist using CTA were determined to be true nodules.

Specificity gain

At baseline, the CAD system had moderate sensitivity of 71% and very low specificity, according to the authors. However, when used as a second reader by the experienced radiologist, specificity increased to 78% (and to 80% when easy-to-dismiss nodules were excluded).
Accuracy with the radiologist was 74%. However, five CAD ROIs determined to be true nodules by CTA were dismissed, representing 10% of all true nodules originally found by CAD.

The evolution of CAD’s routine use with CT and x-ray in detecting cancerous lesions comes with a crucial caveat.
“The device performed extremely well when [used] as it’s intended, and that’s as a second read or an assistant to the radiologist,” Moore said. “Blind use of any CAD device … is totally inappropriate because the devices are designed to be highly sensitive, but not necessarily very specific, which is why the radiologist really needs to interact with these tools as much as possible.”

The researchers acknowledged several limitations to their study. First, it did not attempt to determine a correlation between the chest radiography reports and CAD results. If all nodules seen by the CAD system were also seen by the radiologist, the system would offer little benefit.

The study notes a potential downside to the use of CAD that was not evaluated in the study. If there were no additional findings and there was an average of 0.48 false positives per case, there could be a deleterious effect on the specificity of the radiologist.
The researchers recognized CTA with 1.25-mm images as an excellent method to evaluate the lungs, but added it is not the gold standard.

They also observed that a potential population bias could have been introduced via the emergency department physician ordering trend. If the ED physicians noted a lung nodule on chest radiography, they may have been more likely to order a CTA, according to the authors.

Health Imaging News | May 18, 2010 | Clinical Studies

When used in conjunction with an experienced radiologist, the use of computer-aided detection (CAD) for lung nodule detection on chest radiograph with CT angiography (CTA) correlation presents very good sensitivity, specificity and accuracy, according to a study published online March 31 in the Journal of Digital Imaging.

William Moore, MD, and colleagues from the Stony Brook University Hospital in Stony Brook, N.Y., utilized a varied patient population of those referred to CTA of the chest for the detection of lung nodules, to determine the sensitivity and specificity of a commercially available CAD system for detection of lung nodule on posterior-anterior (PA) chest radiograph. Noting that while chest radiographs usually identify lung nodules, there is a chance that lung cancer can be missed even though they may have been present on the initial study.

“Although there are several commercially available CAD platforms, the exact sensitivity and specificity of these devices have not been fully tested in a general population,” wrote the authors.

The researchers collected all CTA chest studies conducted from November 2007 to November 2008 for review and these studies were then cross referenced for patients who had a PA radiograph within a 24-hour time frame. After selection of 240 chest radiographs consisting of 86 male and 154 female patients ranging in age from 16 to 88 years, the studies were sent to an FDA-approved chest radiograph CAD system (IQQA-Chest, EDDA Technology) for review and all 240 cases presented a CAD result, said the authors.

Following review by CAD, a radiologist with five years of experience and 10 months of CAD experience reviewed all the CAD images and scored the findings on a five-point Likert scale. The CTA was then reviewed to determine if there were correlative nodules, explained the researchers, who noted that the presence of a correlative nodule between 0.5 cm and 1.5 cm was considered a positive result.

Moore and colleagues wrote that there were a total of 69 CTA-confirmed nodules in 49 patients from the CAD reading alone, two of which were determined to be malignant. There were a total of 165 CAD findings or regions of interest (ROIs) on the chest radiographs, of which 49 represented actual nodules seen by CTA.

In terms of the 165 CAD findings that were shown to the radiologist, 87 received a score of 1 or 2 by the radiologist and an average of 0.48 false-positive ROIs were observed per chest radiograph. Of the 240 cases, 121 had no CAD-suggested ROI and in the remaining 119 patients, 85 had false-positive ROIs, one case had four false-positive ROIs, six had three false positive ROIs and 15 cases had two false-positive ROIs. The remaining 64 patients had one ROI.

“We found that this chest radiograph CAD system had a moderate sensitivity of 71 percent and a very low specificity at baseline. However, if the CAD was used as an interactive tool, we found a significant increase in the specificity to 78.1 percent, concluded the researchers. “Accuracy of 73.7 percent was achieved when the CAD device was used with an experienced radiologist.”

Last updated on May 18, 2010 at 8:35 pm EST
Copyright © 2010 TriMed Media Group, Inc.

PRINCETON, N.J., Nov. 12, 2009

EDDA Technology today announced the completion of CE mark for its new release of IQQA®-Liver, an advanced clinical application designed to enhance efficiency and precision in liver imaging evaluation and treatment planning.

IQQA®-Liver provides a comprehensive toolset for highly automated quantitative volumetric evaluation of liver, liver lobes and segments, hepatic lesions, and vascular structures including artery, portal veins and hepatic veins from CT data. Powered by innovative technologies, IQQA®-Liver facilitates physician’s fast evaluation of imaging data as well as operative planning simulation of tumor resection and lobular/segmental/vascular separation/quantification/manipulation in real-time. Physicians may in real-time interactively adjust automated computer analysis results to achieve desired outcome typically within minutes.

IQQA®-Liver already has clearance by the FDA and China SFDA, and is currently used by radiologists and surgeons at numerous prestigious liver transplantation/surgery centers worldwide for pre- and post- operative assessment purposes, including University of Colorado Hospitals Denver, Shanghai Zhongshan Hospital, Tianjin First Center Hospital, Beijing You’an Hospital, and etc. Regulatory clearance of IQQA®-Liver in Taiwan is pending.

Through EDDA’s proprietary IQQA® PACS- and web-enabling technology, IQQA®-Liver can be readily deployed onto any existing hospital PACS workstations or via the web so that data evaluation and treatment planning results can be shared quickly anywhere anytime among authorized physicians.

“Easy-to-use and easy-to-access advanced computer applications for fully quantitative analysis of organs are key to best utilizing the high resolution imaging information for precision treatment planning and post-surgical assessment”, says Dr. Jian-Zhong Qian, President and CEO of EDDA Technology. “EDDA is committed to developing innovative technology and solutions to enhance the application of quantitative imaging to the entire healthcare cycle of patient management.”

Liver disease is among the 10 major causes of death in the US according to the American Liver Foundation. Primary liver cancer, with approximately 1,000,000 cases reported every year in the world, is one of the most common malignancies. Many liver diseases can be potentially treated by surgery or transplantation. The liver is the second most commonly transplanted major organ after the kidney.

EDDA Technology will be exhibiting the IQQA® Family of Products in Booth #9318 at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Nov. 29 – Dec. 3, 2009. Also featured is IQQA®-Chest Enterprise CAD (Computer Aided Detection) designed to assist physician’s detection of small lung nodules from digital chest X-ray. The first prospective study on chest X-ray CAD published in peer-reviewed journal (Academic Radiology Vol. 15:5, pp. 571-575) demonstrated a significant sensitivity increase of physician’s nodule detection from 63.8% without IQQA®-Chest to 92.7% with IQQA®-Chest assistance at University of Iowa’s Carver College of Medicine.

About EDDA Technology
EDDA Technology, Inc. is an innovative clinical computer solution provider in diagnostic imaging and analysis. EDDA offers a series of new generation software products to enable early detection of diseases, and enhance efficiency and precision in diagnosis and treatment. EDDA’s goal is to deliver, with broad accessibility, advanced information analysis technologies that improve clinical workflow and accuracy. A privately held Delaware corporation, EDDA is headquartered in Princeton, New Jersey, and has a subsidiary in Shanghai, China. IQQA® is a registered trademark of EDDA Technology. www.eddatech.com

KYOTO, Japan and PRINCETON, N.J., Nov. 11, 2009

Shimadzu Corporation (Kyoto, Japan) and EDDA Technology Inc. (Princeton, NJ, USA) today announced that both parties have entered into a business partnership on X-ray chest CAD systems based on the Radiography System of Shimadzu featuring its direct conversion flat panel detector (FPD) and EDDA’s CAD applications.

This partnership contains both distribution of EDDA’s chest X-ray CAD applications with Shimadzu’s DR system through Shimadzu’s worldwide sales channel and the development of fully new applications integrating Shimadzu’s state-of-the-art application for digital radiography together with EDDA’s sophisticated technology in the field of chest CAD.

Chest X-ray CAD (Computer Aided Detection) is an advanced clinical application aiming the improvement of physician’s detection accuracy of lung nodules by identifying possible nodules efficiently using computer image analysis technology, which will also help to overcome the challenge of workload of physicians in the diagnosis process. Chest X-ray is the most commonly performed radiographic exam accounting for nearly 50% of all imaging tests, and over 70 million chest X-rays are performed yearly in the US.

EDDA is a pioneer in the area of chest CAD application. Its IQQA®-Chest CAD product is already approved by FDA, EU CE and China SFDA, and is sold and used in USA, Europe, China and other countries. The first prospective study on chest X-ray CAD published in peer-reviewed journal showed positive results that suggest the interpretation of chest radiographs for lung nodules can be improved using IQQA®-Chest. Shimadzu will distribute this chest X-ray CAD application with its DR products in worldwide markets (*). Both companies are working together to prepare another innovative new chest CAD application which shall be introduced to worldwide markets in the upcoming years.

“According to the statistics such as those from WHO, ratio of death from cancer in the recent years tends to be decreasing. However, that from lung cancer is remarkably increasing, ” said Mr. Kunimasa Itoh, general manager, marketing dept., medical systems division of Shimadzu Corporation. “Through the partnership with EDDA, who is expert of application development in this field, we will be able to contribute to improving clinical workflow and quality care of patients by providing advanced image diagnosis solutions to aid in early detection of lung lesions.”

“Our partnership with Shimadzu Corporation reflects the increasingly important role that advanced computer application plays in enhancing clinical workflow to be faster, better and more cost-effective,” said Dr. Jian-Zhong Qian, president and CEO of EDDA Technology. “We are pleased to partner with Shimadzu to offer new solutions to the diagnosis and management of potentially life-threatening lung diseases.”

(* Regulatory approval for the distribution through Shimadzu in Japan and other countries are pending as of this moment.)

For further information please contact:

Shimadzu Corporation
Tetsuya Tanigaki
Public Relations Department
tanigaki@shimadzu.co.jp

EDDA Technology
Xiaolan Zeng
Business and Market Development
xzeng@eddatech.com

About Shimadzu Corporation
Founded in 1875, Shimadzu Corporation, a leader in the development of advanced technologies, has a distinguished history of innovation build on the foundation of contributing to society through science and technology. Shimadzu maintain a global network of sales, service, technical support and applications centers on six continents, and have established long-term relationship with a host of highly trained distributors located in over 100 countries.

About EDDA Technology
EDDA Technology, Inc. is an innovative clinical computer solution provider in diagnostic imaging and analysis. EDDA offers a series of new generation software products to enable early detection of diseases, and enhance efficiency and precision in diagnosis and treatment. EDDA’s goal is to deliver, with broad accessibility, advanced information analysis technologies that improve clinical workflow and accuracy. A privately held Delaware corporation, EDDA is headquartered in Princeton, New Jersey, and has a subsidiary in Shanghai, China. IQQA® is a registered trademark of EDDA Technology. www.eddatech.com

Editor’s Note:
EDDA Technology will be exhibiting in Booth # 9318, and Shimadzu Corporation in Booth #5000, of McCormick Place in Chicago at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Nov. 29 – Dec. 3, 2009.